HI Baldwidx,
Regarding your concern, I refer to the NEU/Acadia announcement that discusses the agreement:
"Neuren has also granted to Acadia an exclusive worldwide licence to develop and commercialise NNZ2591 for Rett syndrome and Fragile X syndrome only. This enables coordinated global development, replacing the restrictions in the existing agreement on use by Neuren in those two indications.
Potential milestone payments and royalties payable to Neuren for NNZ-2591 in Rett and Fragile X are identical to the trofinetide milestone payments and royalties in each of North America and other regions.
Neuren retains worldwide rights to NNZ-2591 in all other indications and is currently conducting Phase 2 clinical trials in each of Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes, with first top-line results expected in December 2023."
So - based on the above - I read it that its in Acadia's best interests to assist Neuren for NNZ2591 development (for Rett and Fragile X trials), whereby Neuren will receive the same royalties based on the existing Daybue milestone framework.
Also - importantly - NNZ development for the other indications are wholly for Neuren to manage.
Do you see it any differently?
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-133
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.41 |
Change
0.790(3.83%) |
Mkt cap ! $2.698B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.42 | $20.76 | $2.148M | 101.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 290 | $21.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.42 | 133 | 2 |
View Market Depth
| Last trade - 11.53am 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |